

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

CORTEX PHARMACEUTICALS INC/DE/
Form 8-K
July 02, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934

Date of Report (Date of earliest event reported)

July 1, 2002

CORTEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-17951

33-0303583

(State or other jurisdiction of
incorporation)

(Commission File Number)

(I.R.S Employer Identification No.)

15241 Barranca Parkway
Irvine, California

92618

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (949) 727-3157

N/A

(Former name or former address, if changed since last report.)

Item 5. Other Events.

Attached to this report as Exhibit 99.1 is the press release issued by Cortex Pharmaceuticals, Inc. dated July 1, 2002 relating to Shire Pharmaceuticals Group plc's election not to exercise its option to develop certain of Cortex's technology and compounds for the treatment of Attention Deficit Hyperactivity Disorder, which press release is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

| Exhibit Description | Exhibit ----- Number ----- |
|--|-------------------------------------|
| Press Release dated July 1, 2002 | 99.1 |
| Transcript of conference call held July 1, 2002 at 1:30 p.m., Pacific Daylight Time. | 99.2 |

Item 9. Regulation FD Disclosure.

The information provided in connection with Item 9 of this report is being furnished pursuant to Regulation FD of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In accordance with General Instruction B.2 of Form 8-K, the information provided in connection with Item 9 of this report shall not be deemed to be "filed" for purposes of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. The furnishing of the information set forth in connection with Item 9 of this report is not intended to, and does not, constitute a determination or admission as to the materiality or completeness of such information.

Cortex Pharmaceuticals, Inc. held a conference call on Monday, July 1, 2002, at 1:30 p.m., Pacific Daylight Time to discuss issues and answer questions regarding Shire Pharmaceuticals Group plc's election not to exercise its option to develop certain of Cortex's technology and compounds for the treatment of Attention Deficit Hyperactivity Disorder. A copy of the transcript from this conference call is attached to this report as Exhibit 99.2 and is incorporated herein by reference. An audio replay of the conference call will be available through July 12, 2002 by calling (800) 642-1687 or (706) 645-9291.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEX PHARMACEUTICALS, INC.

Date: July 2, 2002

By: /s/ Maria S. Messinger

 Maria S. Messinger
 Vice President, Chief Financial Officer
 and Corporate Secretary

3

EXHIBIT INDEX

Exhibit

Sequential

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

| Number | Description | Page No. |
|--------|--|----------|
| 99.1 | Press Release dated July 1, 2002 | 5 |
| 99.2 | Transcript of conference call held July 1, 2002 at 1:30 p.m., Pacific Daylight Time. | 8 |